Nurix is focused on discovering and developing therapies that modulate the ubiquitin proteasome system (UPS) for the treatment of a broad range of human disorders, most notably cancer.
Total raised: $145.1M
Investors 1
| Date | Name | Website |
| - | The Column... | thecolumng... |
Funding Rounds 2
| Date | Series | Amount | Investors | Deal News |
| 12.03.2020 | - | $120M | - | - |
| 22.05.2014 | Series B | $25.1M | - | - |
Mentions in press and media 3
| Date | Title | Description | Category | Author | Source |
| 13.03.2020 | After Kyme... | Sanofi- and Gilead Sciences-ba... | Biotech | - | fiercebiot... |
| 22.05.2014 | Nurix Rais... | Nurix, Inc., a San Francisco, ... | funding S... | - | finsmes.co... |
| 04.04.2013 | Stealthy b... | Formed in 2009 as Kura Therape... | - | - | medcitynew... |